Compare Mesoblast Limited (MESO) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.

Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.

Rivian (RIVN) trades at $14.33, down 0.07% on the day, with a bearish technical signal from moving averages. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates, but maintained full-year guidance, causing mixed market reactions. Financially, revenue growth continues while losses narrow, with a net income margin of -54.95% in 2025. Analyst consensus is a Buy with a $16.89 price target, though cash burn remains a concern with negative operating cash flow.

Rivian's outlook hinges on scaling R2 production and advancing autonomy, offering growth potential, but high cash burn, competitive pressures, and execution risks pose significant challenges. The stock presents a speculative opportunity for investors betting on EV adoption and operational improvements, balanced by substantial financial and market volatility risks.